GlassScriptPhysician profile
Benjamin Fusman
NPI 1376540351
$2,185.27
in general payments reported to CMS, 2019-2025
30 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $57.45 · 2021: $279 · 2022: $319 · 2023: $460 · 2024: $396 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $313.19 | 2019-2024 | |
| Abbott Laboratories | $258.36 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx, Cardiomems |
| Medtronic, INC. | $222.84 | 2021-2022 | |
| Heartflow, INC. | $133.18 | 2019-2025 | Ffrct |
| Irhythm Technologies, INC. | $127.07 | 2019-2022 | |
| Boston Scientific Corporation | $117.87 | 2019-2023 | Avvigo Guidance System |
| Shockwave Medical, INC | $102.60 | 2021 | |
| Novo Nordisk INC | $90.49 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Baxter Healthcare | $83.82 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $74.91 | 2021-2023 | Verquvo |
| Abiomed | $71.11 | 2019-2025 | |
| Pfizer INC. | $68.41 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $52.68 | 2019-2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $47.70 | 2019-2022 | |
| Esperion Therapeutics, INC. | $42.70 | 2025 | Nexletol |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.30 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $41.82 | 2019-2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.97 | 2019-2025 | Lifevest |
| Biosense Webster, INC. | $34.32 | 2019 | |
| Amarin Pharma, INC. | $31.87 | 2019-2022 | |
| Atricure, INC. | $31.70 | 2023 | |
| Impulse Dynamics (USA) INC. | $30.11 | 2024 | Optimizer |
| Cardiva Medical, INC. | $23.96 | 2024 | Optowire |
| Penumbra, INC. | $18.95 | 2021 | |
| Kestra Medical Technology Services, INC. | $17.86 | 2024 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $16.22 | 2025 | Evkeeza |
| Kiniksa Pharmaceuticals, LTD. | $14.64 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.63 | 2020 | |
| Amgen INC. | $11.62 | 2019 | |
| Cardiovascular Systems INC. | $9.37 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Fusman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.